
    
      Protocol 13VR3 is a multi-center, open-label study assessing long-term somavaratan
      administration. It is open to subjects completing a somavaratan study in children with growth
      hormone deficiency (GHD), as well as up to 100 new treatment na√Øve subjects with GHD. All
      subjects will receive somavaratan 3.5 mg/kg twice monthly. The study will be conducted at
      approximately 70 Pediatric Endocrinology centers in the United States, Canada, and Europe.
    
  